Sheng-Fung Lin
- Epidemiology top 5%
- Hepatology top 2%
- Oncology top 10%
- Neurology
- Molecular Biology
- Co-authors
- Hui‐Jen TsaiLi‐Tzong ChenMing-Chung WangPei‐Jer ChenHwei‐Fang TienTsang-Wu LiuAnn‐Lii ChengChiun Hsu
- Topics
- Multiple Myeloma Research and Treatments (4 papers)Protein Degradation and Inhibitors (3 papers)Lymphoma Diagnosis and Treatment (3 papers)
- Cited by
- HepatologyEpidemiologyOncology
- Journals
- PLoS ONEHepatologyScientific Reports
- Partner nations
- TaiwanUnited StatesChina
In The Last Decade
Sheng-Fung Lin
16 papers receiving 752 citations
Peers
Comparison fields: 5 of 65
- Epidemiology 551
- Hepatology 390
- Oncology 234
- Neurology 82
- Molecular Biology 73
Countries citing papers authored by Sheng-Fung Lin
This map shows the geographic impact of Sheng-Fung Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng-Fung Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng-Fung Lin more than expected).
Fields of papers citing papers by Sheng-Fung Lin
This network shows the impact of papers produced by Sheng-Fung Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng-Fung Lin. The network helps show where Sheng-Fung Lin may publish in the future.
Co-authorship network of co-authors of Sheng-Fung Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Sheng-Fung Lin. A scholar is included among the top collaborators of Sheng-Fung Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng-Fung Lin. Sheng-Fung Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 4 | |
| 3 | 5 | |
| 4 | 61 | |
| 5 | 7 | |
| 6 | 10 | |
| 7 | 2 | |
| 8 | 35 | |
| 9 | 19 | |
| 10 | 9 | |
| 11 | 15 | |
| 12 | 207 | |
| 13 | 132 | |
| 14 | 5 | |
| 15 | Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial. | 8 |
| 16 | 230 | |
| 17 | 11 |
About Sheng-Fung Lin
Sheng-Fung Lin is a scholar working on Hematology, Anesthesiology and Pain Medicine and Oncology, having authored 17 papers that have together received 760 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Hepatology (390 citations), Epidemiology (551 citations) and Oncology (234 citations). Sheng-Fung Lin has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Hui‐Jen Tsai, Li‐Tzong Chen, Ming-Chung Wang, Pei‐Jer Chen, Hwei‐Fang Tien, Tsang-Wu Liu, Ann‐Lii Cheng, Chiun Hsu, Jeffrey S. Chang and Chia-Rung Tsai. Their work appears in journals such as PLoS ONE, Hepatology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.